Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 5 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
ESC 24: The POPular PAUSE TAVI Trial
Author(s): Dirk-Jan van Ginkel Added: 1 year ago
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure.Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital). Presented for the first time at ESC 2024, this multicenter, randomized, open-label clinical trial compared the safety and efficacy of continuous… View more

Anticoagulation

Intervention
AI-ECG Enhances Heart Failure Risk Prediction
Added: 1 day ago Source:  Arrhythmia Academy
Artificial intelligence applied to electrocardiograms (ECG-AI) may offer a scalable way to identify individuals at high risk of developing heart failure (HF), potentially improving on current clinical risk estimators, according to a new pooled cohort analysis from the HeartShare/Accelerating Medicines Partnership (AMP) Heart Failure program.¹The study aimed to assess whether ECG-AI models… View more

Electrophysiology & Arrhythmia

Heart Failure
Managing Hypertension in CVD: How Low Can We Go?
Author(s): Yassir Javaid, Michel Burnier, Mariya Tokmakova ,et al Start date: Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Part 2 - Medical Options for Advanced HFpEF/HFmrEF Patients
Author(s): Biykem Bozkurt, Pardeep Jhund, Muthiah Vaduganathan Start date: Sep 11, 2024
Join us for an unparalleled educational journey dedicated to tackling the complexities of managing HFpEF and HFmrEF patients. This CME-accredited live roundtable is chaired by Dr Biykem Bozkurt (Baylor College of Medicine, US) and features insights from renowned experts Prof Pardeep Jhund (University of Glasgow, UK) and Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical… View more

Heart Failure
Author(s): Apisara Lohachatinante , Nuttanun Kittikunkanyakit , Sayamon Sukkha , et al Added: 1 year ago

Anticoagulation
Research Area(s) / Expertise: Job title: Professor of Medicine in the Division of Nephrology
Dr Navdeep Tangri is a Professor of Medicine in the Division of Nephrology at University of Manitoba, Winnipeg, CA.Dr Tangri's research programme is focused on the clinical management of patients with advanced chronic kidney disease. He developed the kidney failure risk equation (KFRE) to predict the need for dialysis in patients with chronic kidney disease. View more
Obituary: Amir Lerman, MD
Author(s): Amir Lerman Added: 15 hours ago
Empagliflozin and Finerenone: Hyperkalemia Risk in CKD
Added: 6 days ago Source:  Radcliffe CVRM
The CONFIDENCE trial investigated the efficacy of dual Empagliflozin & Finerenone therapy in compound CKD-T2D patients compared to Finerenone monotherapy in hyperkalemia prevention. The results suggested that dual therapy did not significantly mitigate hyperkalemia risk compared to solitary Finerenone administration.¹MethodologyThe CONFIDENCE trial was a double-blind, randomised, controlled study… View more

Cardiovascular Renal Metabolic